Anika Therapeutics (ANIK) Tops Q2 EPS by 35c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.50 +1.56%
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
LUNA, BTTX, VAXX, More
Financial Fact:
Diluted weighted average common shares outstanding: 15.08M
Today's EPS Names:
LUNA, BTTX, VAXX, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.68, $0.35 better than the analyst estimate of $0.33. Revenue for the quarter came in at $30.5 million versus the consensus estimate of $27.9 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform
- CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
